Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 185 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Refractory Epilepsy Clear all
Recruiting Not applicable Interventional

Temporal Interference Brain Stimulation for Adults With Drug-Resistant Epilepsy Undergoing Stereo-EEG Monitoring

NCT07764718
View directory record Official record
Conditions
Drug-Resistant Focal Epilepsy
Interventions
Temporal Interference Stimulation, Direct Electrical Stimulation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 9:54 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

NCT01142193
View directory record Official record
Conditions
Epilepsy
Interventions
USL255, Placebo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Ventura, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 21, 2026, 9:54 AM EDT
Completed Phase 1 Interventional

Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy

NCT01703143
View directory record Official record
Conditions
Epilepsy
Interventions
Laser ablation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 21, 2026, 9:54 AM EDT
No Longer Available No phase listed Expanded access

Stiripentol in Dravet Syndrome

NCT01533506
View directory record Official record
Conditions
Dravet Syndrome
Interventions
stiripentol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
11 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 21, 2026, 9:54 AM EDT
Not yet recruiting Not applicable Interventional

Acute Stimulation and Modulation of Stereotyped High-Frequency Oscillations

NCT06898138
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Interchange System
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 9:54 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00448539
View directory record Official record
Conditions
Refractory Partial Onset Seizures
Interventions
Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bradenton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 21, 2026, 9:54 AM EDT
Completed Not applicable Interventional

Use of the Atkins Diet for Adults With Intractable Epilepsy

NCT00121927
View directory record Official record
Conditions
Epilepsy
Interventions
Atkins diet (15 grams/day carbohydrates)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Oct 21, 2026, 9:54 AM EDT
Completed No phase listed Observational

Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings

NCT00071305
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 9:54 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141
View directory record Official record
Conditions
Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions
Perampanel Oral Suspension, Perampanel Tablet
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 9:54 AM EDT
Completed Not applicable Interventional Results available

Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy

NCT01772654
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Arterial Spin Labeled (ASL) MRI sequence
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 9:54 AM EDT
Completed No phase listed Observational

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

NCT00001666
View directory record Official record
Conditions
Partial Epilepsy, Seizures
Interventions
Cadwell High-Speed Magnetoelectric Stimulator, Magpro High-Speed Magnetoelectric Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 9:54 AM EDT
Completed Phase 3 Interventional

Depression and Health Outcomes in Refractory Epilepsy

NCT00026637
View directory record Official record
Conditions
Depression, Epilepsy
Interventions
sertraline, cognitive behavior therapy
Drug · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 21, 2026, 9:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

NCT05503511
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (bumetanide analog) or Matching Placebo
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 21, 2026, 9:54 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

NCT04106219
View directory record Official record
Conditions
Neuroblastoma
Interventions
LY3295668 Erbumine, Topotecan, Cyclophosphamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 21 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 9:54 AM EDT
Not listed Not applicable Interventional

Decreasing Parental Stress of Caregivers of Infants With Infantile Spasms by Using Telemedicine Technology

NCT04086992
View directory record Official record
Conditions
Infantile Spasms, Non-Intractable
Interventions
Remote monitoring
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 30 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 21, 2026, 9:54 AM EDT
Recruiting Not applicable Interventional

Diagnosing Epilepsy To EffeCT Change

NCT07110337
View directory record Official record
Conditions
Epilepsy, Epilepsy (Treatment Refractory)
Interventions
Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)
Device
Lead sponsor
Epiminder America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 9:54 AM EDT
Enrolling by invitation Not applicable Interventional

Neural Computations of Goal-directed Decision-making

NCT06489561
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 9:54 AM EDT
Recruiting Not applicable Interventional

Overnight TI in TLE

NCT07434986
View directory record Official record
Conditions
Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy, Sleep
Interventions
Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

NCT00152451
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (ucb 44212)
Drug
Lead sponsor
UCB S.A. - Pharma Sector
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 21, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383
View directory record Official record
Conditions
Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 21, 2026, 9:54 AM EDT
Enrolling by invitation Not applicable Interventional

Electrochemical and Electrophysiological Study

NCT05273970
View directory record Official record
Conditions
Cognition, Medically Intractable Epilepsy
Interventions
Behavioral testing under intracranial monitoring
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 21, 2026, 9:54 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy

NCT01906398
View directory record Official record
Conditions
Epilepsy
Interventions
ketogenic diet
Other
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 21, 2026, 9:54 AM EDT
Completed Phase 3 Interventional Results available

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

NCT00232596
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 21, 2026, 9:54 AM EDT